Ravandi Farhad
MD Anderson Cancer Center, University of Texas, Houston, TX, USA,
Curr Hematol Malig Rep. 2014 Jun;9(2):144-7. doi: 10.1007/s11899-014-0204-7.
Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.
尽管联合化疗方案在治疗一部分急性白血病患者方面已取得显著成功，但我们可能已接近从这些联合方案中获得最大益处的极限。确定细胞信号通路中的靶点并开发针对这些靶点的特异性药物，丰富了我们的治疗手段；我们当前面临的挑战是如何将这些药物最佳地纳入现有的治疗方案中。
